G protein-receptor kinases 5/6 are the key regulators of G protein-coupled receptor 35-arrestin interactions.

G protein–coupled receptor kinases GPR35 arrestins phospho-site–specific antisera phosphorylation

Journal

The Journal of biological chemistry
ISSN: 1083-351X
Titre abrégé: J Biol Chem
Pays: United States
ID NLM: 2985121R

Informations de publication

Date de publication:
Oct 2023
Historique:
received: 19 04 2023
revised: 07 08 2023
accepted: 17 08 2023
pubmed: 4 9 2023
medline: 4 9 2023
entrez: 3 9 2023
Statut: ppublish

Résumé

Human G protein-coupled receptor 35 is regulated by agonist-mediated phosphorylation of a set of five phospho-acceptor amino acids within its C-terminal tail. Alteration of both Ser

Identifiants

DOI: 10.1016/j.jbc.2023.105218 PMID: 37660910 PMC: PMC10520886
pubmed: 37660910
pii: S0021-9258(23)02246-9
doi: 10.1016/j.jbc.2023.105218
pmc: PMC10520886
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

105218

Informations de copyright

Copyright © 2023 The Authors. Published by Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Conflict of interest The authors declare that they have no conflicts of interest with the contents of this article.

Auteurs

Amlan Ganguly (A)

Centre for Translational Pharmacology, School of Molecular Biosciences, Advanced Research Centre (ARC), College of Medical, Veterinary and Life Sciences University of Glasgow, Glasgow, UK.

Tezz Quon (T)

Centre for Translational Pharmacology, School of Molecular Biosciences, Advanced Research Centre (ARC), College of Medical, Veterinary and Life Sciences University of Glasgow, Glasgow, UK.

Laura Jenkins (L)

Centre for Translational Pharmacology, School of Molecular Biosciences, Advanced Research Centre (ARC), College of Medical, Veterinary and Life Sciences University of Glasgow, Glasgow, UK.

Babu Joseph (B)

Drug Discovery Program, Ontario Institute for Cancer Research, MaRS Centre, Toronto, Ontario, Canada.

Rima Al-Awar (R)

Drug Discovery Program, Ontario Institute for Cancer Research, MaRS Centre, Toronto, Ontario, Canada.

Andy Chevigne (A)

Division of Immuno-Pharmacology and Interactomics, Department of Infection and Immunity, Luxembourg Institute of Health, Esch-sur-Alzette, Luxembourg.

Andrew B Tobin (AB)

Centre for Translational Pharmacology, School of Molecular Biosciences, Advanced Research Centre (ARC), College of Medical, Veterinary and Life Sciences University of Glasgow, Glasgow, UK.

David E Uehling (DE)

Drug Discovery Program, Ontario Institute for Cancer Research, MaRS Centre, Toronto, Ontario, Canada.

Carsten Hoffmann (C)

Institute for Molecular Cell Biology, CMB-Center for Molecular Biomedicine, University Hospital Jena, Friedrich Schiller University Jena, Jena, Germany.

Julia Drube (J)

Institute for Molecular Cell Biology, CMB-Center for Molecular Biomedicine, University Hospital Jena, Friedrich Schiller University Jena, Jena, Germany.

Graeme Milligan (G)

Centre for Translational Pharmacology, School of Molecular Biosciences, Advanced Research Centre (ARC), College of Medical, Veterinary and Life Sciences University of Glasgow, Glasgow, UK. Electronic address: Graeme.Milligan@glasgow.ac.uk.

Classifications MeSH